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Abstract
Objectives⁄methods: This 1-yr prospective phase II trial evaluated the efﬁcacy of deferasirox in regularly
transfused patients aged 3–81 yrs with myelodysplastic syndromes (MDS; n = 47), Diamond–Blackfan
anaemia (DBA; n = 30), other rare anaemias (n = 22) or b-thalassaemia (n = 85). Dosage was determined
by baseline liver iron concentration (LIC). Results: In patients with baseline LIC ‡7m gF e⁄g dry weight,
deferasirox initiated at 20 or 30 mg⁄kg⁄d produced statistically signiﬁcant decreases in LIC (P < 0.001);
these decreases were greatest in MDS and least in DBA. As chelation efﬁciency and iron excretion did
not differ signiﬁcantly between disease groups, the differences in LIC changes are consistent with mean
transfusional iron intake (least in MDS: 0.28 ± 0.14 mg⁄kg⁄d; greatest in DBA: 0.4 ± 0.11 mg⁄kg⁄d). Over-
all, LIC changes were dependent on dose (P < 0.001) and transfusional iron intake (P < 0.01), but not sta-
tistically different between disease groups. Changes in serum ferritin and LIC were correlated irrespective
of disease group (r = 0.59), supporting the potential use of serum ferritin for monitoring deferasirox ther-
apy. Deferasirox had a safety proﬁle compatible with long-term use. There were no disease-speciﬁc
safety⁄tolerability effects: the most common adverse events were gastrointestinal disturbances, skin rash
and non-progressive serum creatinine increases. Conclusions: Deferasirox is effective for reducing iron
burden with a deﬁned, clinically manageable safety proﬁle in patients with various transfusion-dependent
anaemias. There were no disease-speciﬁc adverse events. Once differences in transfusional iron intake
are accounted for, dose-dependent changes in LIC or serum ferritin are similar in MDS and other disease
groups.
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the treatment of transfusional iron overload has largely
been obtained based on experience in patients with b-
thalassaemia major (1–3). In the USA, the myelodys-
plastic syndromes (MDS) are a frequent cause of trans-
fusional iron overload, with an estimated 15 000 new
cases each year (4). Recent data suggest that secondary
iron overload is negatively associated with survival in
transfusion-dependent MDS patients, with a hazard
ratio of 1.3 for every 500 lg⁄L increase in serum ferri-
tin level >1000 lg⁄L (5). Iron accumulation in the
myocardium, a potential cause of death, is known to
occur in MDS and related conditions in the absence of
chelation therapy (6, 7). Deferoxamine (Desferal
 ,
DFO, Novartis Pharma AG, Basel, Switzerland)
induces urinary iron excretion and decreases levels of
serum ferritin, liver iron (8) and heart iron (7) in
MDS. However, the efﬁcacy of iron chelation in MDS
has not previously been compared directly with that of
b-thalassaemia. Response to chelation therapy in MDS
may not be the same as that in thalassaemia syndromes
and other anaemias, as the degree of ineffective ery-
thropoiesis and thus the magnitude of chelatable iron
pools may differ. Furthermore, it is likely that trans-
fusion requirements are more heterogeneous in MDS
than in b-thalassaemia. Prospective comparisons of
response to chelation therapy in MDS and thalassaemia
would allow evidence-based therapeutic decisions about
optimal dosing regimens.
DFO has been used clinically for more than 40 yr,
although the difﬁculties in complying with treatment
are well recognised. Subcutaneous infusions may be
particularly troublesome in patients with MDS, who
are typically elderly and may have decreased platelet
counts or platelet dysfunction, leading to bruising at
the infusion site. This has led to the need for a conve-
nient oral chelator that can reduce or maintain body
iron stores in regularly transfused patients who are iron
overloaded. Deferasirox (Exjade
 , ICL670, Novartis
Pharma AG, Basel, Switzerland), a once-daily, oral iron
chelator for the treatment of chronic iron overload, has
been shown to be effective as monotherapy in main-
taining or decreasing iron loading in b-thalassaemia (9–
12). Evidence for the efﬁcacy and tolerability of defer-
asirox in MDS and rare anaemias associated with
transfusional iron overload also needs to be established.
In this prospective, 1-yr multicentre study, the efﬁcacy
and safety of deferasirox have been investigated in
MDS, Diamond–Blackfan anaemia (DBA) or other
anaemias and in b-thalassaemia. Treatment response,
according to dose and the rate of iron accumulation
from blood transfusions, has been compared between
the different anaemias, allowing inferences about
optimal dosing schedules to be made. The relationship
between change in liver iron concentration (LIC) and
serum ferritin has also been compared between the dif-
ferent disease groups, enabling inferences to be made
about the value of sequential ferritin monitoring in
these conditions. This study constitutes the largest pro-
spective trial ever undertaken on the effects of iron
chelation in MDS, DBA and rare transfusion-dependent
anaemias.
Patients and methods
Eligibility and enrolment procedures
Eligible patients included males and females aged ‡2y r
with a diagnosis of transfusion-dependent anaemia
(excluding sickle cell anaemia), who required ‡8 blood
transfusions per year and had a LIC ‡2m g F e⁄g dry
weight (dw). Patients were required to have a life expec-
tancy >1 yr, although no criteria for morphological or
prognostic classiﬁcation were included for MDS. Patients
with b-thalassaemia, who were non-compliant (having
taken <50% of the prescribed DFO dose in the preced-
ing 12 months, with LIC >14 mg Fe⁄g dw), intolerant
of, or inadequately responsive to DFO treatment, were
also included. Those patients who had previously
received deferiprone (Ferriprox
 , Apotex Inc., Toronto,
ON, Canada) discontinued treatment at least 28 d before
initiating deferasirox therapy. Patients with serum creati-
nine levels above the upper limit of normal (ULN) at
baseline were excluded from the trial. Further exclusion
criteria and enrolment procedures, including provision of
informed consent, were as previously described (9).
Treatment plan
Deferasirox was administered once daily as a suspension
in water, 30 min before breakfast, for 1 yr. A dosing
algorithm was used as previously reported (9), such that
patients with baseline LIC of 2–3, >3–7, >7–14 and
>14 mg Fe⁄g dw were assigned to deferasirox doses of
5, 10, 20 and 30 mg⁄kg⁄d, respectively. As per the proto-
col, blood transfusions were regularly administered dur-
ing the study period according to the patients’
requirements as judged by the investigators, with the aim
of maintaining haemoglobin levels ‡8g⁄dL. The amount
of transfusional iron received by each patient was deter-
mined using the actual haematocrit of the transfused
units or on an average haematocrit for similar units pre-
pared in the same blood bank. Therapy was only inter-
rupted at the discretion of the investigator for
intercurrent illness, adverse events, or protocol-deﬁned
laboratory test results, such as increases in serum creati-
nine levels.
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In 65.2% of patients, LIC was determined by ultra-
sound-guided percutaneous liver biopsy (13) using a
single central laboratory (Clinique des Maladies du Foie,
Centre Hospitalier Universitaire, Rennes, France) on
samples transported as parafﬁn-embedded blocks (14). In
paediatric or other patients where biopsy was considered
impractical or contraindicated (e.g. because of thrombo-
cytopenic bleeding disorders in patients with MDS), LIC
was measured by the non-invasive technique of magnetic
liver susceptometry using a superconducting quantum
interference device (SQUID) (15) in three centres (Turin,
Italy; Hamburg, Germany; Oakland, USA). At the end
of the 1-yr treatment period, it was planned that all
patients had a repeat LIC determination using the same
methodology as the initial determination (liver biopsy or
SQUID).
Calculation of iron intake and net body iron balance
Net body iron balance (also called total body iron
excretion) was calculated based on the amount of red
blood cells (RBCs) transfused (iron intake in
mg = Kin) and on the changes in total body iron
stores, calculated from LIC changes (baseline to study
end) (16, 17) as described previously (9). Transfusional
iron intake was calculated from the total amount of
transfused blood, taking into account the haematocrit
of each unit. In case of missing data, either the aver-
age haematocrit of the respective blood bank centre
was used or one RBC unit was calculated to contain
200 mg of iron.
Efﬁcacy assessments
The primary endpoint of this trial was the binary suc-
cess criterion deﬁned by maintenance or reduction of
LIC based on patients’ baseline LIC. For patients with
baseline LIC of 2 to <10 mg Fe⁄g dw, success was
deﬁned as an LIC after 1 yr of 1 to <7 mg Fe⁄gd w
(failure was <1 or ‡7m gF e⁄g dw). For patients with
baseline LIC of ‡10 mg Fe⁄g dw, success was deﬁned
as a decrease in LIC after 1 yr of ‡3m gF e⁄g dw (fail-
ure as decrease in LIC <3 mg Fe⁄g dw). If no LIC
determination was available at the end of study, these
patients were considered as non-responders. Secondary
efﬁcacy endpoints included evaluation of the change in
LIC and serum ferritin levels over time. The key sec-
ondary criterion was to show a signiﬁcant reduction in
LIC in patients with baseline LIC ‡7m gF e⁄g dw and
available values at end of study. Chelator efﬁciency,
which can be deﬁned as the amount of iron excretion
expressed as a percentage of the theoretical iron-
binding capacity of chelator dose (18), was calculated
for all doses pooled.
Safety assessments
Assessments for safety were performed at monthly
intervals at a central laboratory (BARC Laboratories,
Gent, Belgium), and included a complete blood count
and differential, electrolytes, liver function tests, trace
element and urinary protein⁄creatinine analyses.
Electrocardiograms (ECGs) and ophthalmological and
auditory examinations were performed every 3 months.
For patients less than 16 yr of age, additional evalua-
tions included assessment of growth rate and sexual
development.
Statistical methods and sample size determination
The size of the trial was determined to demonstrate, at
the one-sided alpha level of 0.025, that the success rate
is >50% provided that the true rate is 65%. In order
to achieve 90% power, 113 patients were required to
be recruited. However, the planned sample was
increased to 175 patients to improve the representation
of disease subgroups. The CIs for the success rates
were calculated using the normal approximation.
Student’s t-test was used to test reduction of LIC in
patients with LIC ‡7m gF e⁄g dw at baseline. To eval-
uate the relationship between changes in serum ferritin
and LIC, an exploratory linear regression model was
ﬁtted with change in LIC as dependent variable and
the following covariates: serum ferritin change, disease
group and serum ferritin change by disease group inter-
action. Further analyses were exploratory and described
in the text.
Quality control, quality assurance and monitoring
This trial was conducted in accordance with Good Clini-
cal Practices, as outlined in the International Conference
on Harmonization guidelines. Institutional Review Board
or Ethics Committee approval was obtained at each par-
ticipating institution and written informed consent was
obtained from all patients or their legal guardians prior
to participation in any study procedures.
A Study Monitoring Committee comprising four inves-
tigators supervised the trial conduct and made decisions
regarding dose adjustment for individual patients. An
independent Programme Safety Board monitored the
study.
Patients completing 1 yr on study were eligible to
receive deferasirox as part of an ongoing extension
study.
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Patient population
Of the 184 patients enrolled in this study, 47 had MDS,
30 had DBA, 22 had ‘other anaemias’ (aplastic anaemia,
n =5 ;a-thalassaemia and sideroblastic anaemia, n =3
for both; myeloﬁbrosis, pure red cell aplasia, pyruvate
kinase deﬁciency, n = 2 for each; autoimmune haemolyt-
ic anaemia, Fanconi’s anaemia, hereditary sideroblastic
anaemia, erythropenia and unspeciﬁed anaemia, n =1
for all) and 85 had b-thalassaemia (Table 1). MDS
patients were, on an average, older than the other disease
groups. The proportion of patients with LIC determined
by biopsy was 78.8% for b-thalassaemia, 46.8% for
MDS and 56.7% for DBA.
In this study, LIC values obtained by SQUID were, on
an average, >50% lower than those obtained by biopsy
(mean baseline LIC 9.5 ± 5.4, n = 46 vs. 21.9 ± 10.3,
n = 101, respectively). These observations are consistent
with a cross-validation substudy that found a similar dis-
cordance in some patients whose LIC was determined
using both methods (overall LIC by SQUID was half that
of LIC by biopsy) (19). As a result, patients with LIC
assessed by SQUID may have been assigned to a lower
dose of deferasirox than if they had received a biopsy.
Based on results from the cross-validation substudy, for
the purposes of this analysis, LIC values obtained by
SQUID have been multiplied by a factor of two to correct
for the discrepancy in LIC values obtained from SQUID
compared with biopsy. Based on this correction, 93% of
patients had baseline LIC ‡7m g F e⁄g dw. Of these
patients, 92% had been treated with 20 or 30 mg⁄kg⁄d,
while the remainder had been assigned to lower doses
based on their baseline SQUID value.
Patient exposure to treatment
Prior to enrolment, 135 patients (73.4%) had received
iron chelation therapy with DFO and 24 patients
(13.0%) had received deferiprone. Baseline LIC was
comparable between disease groups.
Most of the patients (85.9%) were assigned to 20 or
30 mg⁄kg daily doses. Dose adjustments, mainly inter-
ruptions or decreases, were made in 89 patients (48.4%)
and were primarily due to adverse events or based on
deﬁned laboratory test results. Four patients, originally
assigned 5 or 10 mg⁄kg⁄d, were escalated to a higher
dose after a mean of 37.4–38.0 wk.
Table 1 Baseline characteristics, exposure and
disposition MDS
(n = 47)
DBA
(n = 30)
Other
anaemias
(n = 22)
b-Thalassaemia
(n = 85)
Age, yr
Mean 65.1 16.1 35.8 24.7
Range 20–81 3–42 4–80 4–59
Baseline LIC, mg Fe⁄gd w
Mean 20.7 23.4 18.7 21.2
Range 4.8–51.3 4.6–42.7 8.6–40.4 2.3–59.0
‡7, % 89.4 96.7 100 92.9
Baseline serum ferritin, lg⁄L
Mean 3343 3245 3144 4321
Range 537–9099 840–11 854 1077–7351 440–13 943
Average iron intake
1,m g⁄kg⁄d
Mean 0.28 0.40 0.31 0.35
Range 0–0.52 0.13–0.63 0–0.61 0.11–0.8
Mean daily dose, mg⁄kg 20.0 23.6 21.9 23.8
5, % 8.5 3.3 – 2.4
10, % 14.9 10.0 4.5 9.4
20, % 25.5 26.7 45.5 25.9
30, % 51.1 60.0 50.0 62.4
Mean exposure, wk 38.6 51.6 46.8 51.2
Patients discontinued, % 38.3 3.3 22.7 9.4
Death 8.5 3.3 – –
Withdrawal for safety 14.9 – 9.1 4.7
Withdrawal, other
reasons
2
14.9 – 13.6 4.7
1Two RBC units of blood⁄month = 0.263 mg⁄kg⁄d of iron (assuming that 1 unit = 185 mL
packed RBC = 200 mg iron, and a patient weight of 50 kg);
2Includes study drug no longer
required and withdrawal of consent.
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treatment, of whom 147 (79.9%) had baseline and
end-of-study LIC measurements (101 by biopsy, 46 by
SQUID). Of the 46 patients evaluated by SQUID, 15,
12, 4 and 15 were MDS, DBA, other anaemia and b-
thalassaemia patients, respectively (53.6, 46.2, 23.5 and
19.7% of the respective populations).
Success rates
The overall success rate was 50.5% [n = 184, 95% CI
(43.3, 57.8)]. However, excluding patients without a
LIC assessment at end of study, the overall success
rate was 63.3% [n = 147, 95% CI (55.5, 71.1)]. Suc-
cess rates in the MDS, DBA, other anaemia and
b-thalassaemia disease groups were 78.6% (63.4, 93.8),
53.8% (34.7, 73.0), 70.6% (48.9, 92.2) and 59.2%
(48.2, 70.3), respectively, in patients with available LIC
assessment at end of study (see Table 2 for sample
sizes).
Changes in liver iron concentration
Table 2 shows changes in LIC in each disease group
according to the initial dose received in patients with
LIC measured at study end. The overall mean change in
LIC in the 125 patients with baseline LIC ‡7m gF e⁄g
dw who were treated with deferasirox 20 or 30 mg⁄kg⁄d
was )6.0 ± 7.8 mg Fe⁄gd w( P < 0.001; 1-sample Stu-
dent’s t-test). The LIC decreases in these patients were
also statistically signiﬁcant in the MDS, DBA, other
anaemia and b-thalassaemia disease groups [)9.9 ± 5.5
(n = 19), )3.7 ± 7.7 (n = 22), )3.8 ± 7.1 (n = 17)
and )6.2 ± 8.2 (n = 67) mg Fe⁄g dw, respectively;
P < 0.001 for MDS and b-thalassaemia, P = 0.036 for
DBA and P = 0.044 for other anaemias]. A separate
pooled analysis of all patients evaluated by SQUID
(uncorrected) or biopsy demonstrated LIC changes of
)1.9 ± 3.8 and )3.9 ± 4.4 mg Fe⁄g dw, respectively,
for patients on 20 mg⁄kg⁄d and )3.6 ± 2.3 and
)7.0 ± 8.5 mg Fe⁄g dw, respectively, for patients on
30 mg⁄kg⁄d. Changes in LIC over 1 yr were categorised
as increase vs. no increase, which is independent of the
absolute magnitude of change. All patients (19⁄19) with
MDS who received 20 or 30 mg⁄kg⁄d had a reduction in
LIC, while 44% (4⁄9) of the patients who were treated
with 5 or 10 mg⁄kg⁄d also had a reduction. This com-
pares with 55% (12⁄22) and 25% (1⁄4) of patients with
DBA, respectively, the group which had highest iron
intake during study.
Chelator efﬁciency was not statistically signiﬁcantly
different when compared across disease groups
(P = 0.19; Table 2) or dose (P = 0.24, linear model
with dose and disease group as main effects).
Changes in serum ferritin
Effects on mean serum ferritin levels over time paral-
leled the dose-dependent changes in LIC (Table 2). A
correlation was observed between changes in serum fer-
ritin and LIC, which was consistent across disease
groups (correlation coefﬁcient = 0.59, P < 0.001;
Fig. 1). Change in ferritin was the only covariate which
had a statistically signiﬁcant effect on change in LIC
(P < 0.001). Thus, the change in serum ferritin in rela-
tion to change in LIC follows a similar relationship for
all disease groups treated with deferasirox. Monthly
monitoring of serum ferritin levels also revealed a simi-
lar dose–response pattern in the MDS and b-thalassae-
mia groups: levels increased with deferasirox 5 mg⁄kg⁄d
and decreased with deferasirox 30 mg⁄kg⁄d, with doses
of 10 and 20 mg⁄kg⁄d generally showing intermediate
effects. Although the number of patients receiving
deferasirox doses of 5 and 10 mg⁄kg⁄d was small, an
Table 2 Changes in LIC and serum ferritin by initial dose and disease group (for patients with end-of-study LIC assessment, n = 147)
Initial dose,
mg⁄kg⁄d
Change in iron burden
(based on available values)
MDS
(n = 28)
DBA
(n = 26)
Other anaemias
(n = 17)
b-Thalassaemia
(n = 76)
5 Patients 3 1 0 1
Change in serum ferritin, lg⁄L 2620 ± 2473 2473 – 2071
Change in LIC, mg Fe⁄g dw 7.4 ± 4.9 7.6 – 11.4
10 Patients 6 3 0 8
Change in serum ferritin, lg⁄L 196 ± 1097 1084 ± 392 – 1116 ± 642
Change in LIC, mg Fe⁄gd w )3.4 ± 5.6 5.7 ± 6.2 – 6.5 ± 3.2
20 Patients 7 7 8 17
Change in serum ferritin, lg⁄L )410 ± 1632 )364 ± 1002 )894 ± 957 385 ± 876
Change in LIC, mg Fe⁄gd w )10.7 ± 5.2 )4.6 ± 6.6 )3.2 ± 7.0 )1.1 ± 4.2
30 Patients 12 15 9 50
Change in serum ferritin, lg⁄L )1581 ± 1653 )143 ± 1328 )443 ± 1906 )1019 ± 1651
Change in LIC, mg Fe⁄gd w )9.4 ± 5.9 )3.2 ± 8.4 )4.4 ± 7.6 )8.0 ± 8.5
All Chelation efﬁciency, % 33.9 ± 20.0 26.7 ± 16.1 26.6 ± 15.0 26.7 ± 12.3
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noted (Table 2). In contrast, patients receiving doses of
20 and 30 mg⁄kg⁄d generally experienced maintenance
or reduction of iron burden.
Outcome of chelation by disease group: impact of
blood transfusion and dose
Average iron intake per kilogram of body weight varied
widely both within and between disease groups (Table 1).
On an average, patients with MDS had the lowest trans-
fusional iron intake (0.28 mg⁄kg⁄d), while those with
DBA had the highest (0.40 mg⁄kg⁄d). These differences
in transfusional iron intake were also reﬂected in the pro-
portions of patients having the lowest transfusional iron
intake, with 53% of MDS patients, but only 20% of
DBA patients requiring <0.3 mg⁄kg⁄d. At 20 and
30 mg⁄kg⁄d, deferasirox stabilised or reduced mean LIC
and serum ferritin levels across a variety of transfusion-
dependent anaemias (Table 2). However, changes in LIC
were most pronounced in MDS ()9.4 mg Fe⁄gd wa t
30 mg⁄kg⁄d) and least pronounced in DBA ()3.2 mg
Fe⁄gd wa t3 0 m g ⁄kg⁄d) and paralleled the relative
changes in serum ferritin of )1581 and )143 lg⁄L,
respectively. When including dose, iron intake category,
disease group and the interaction of iron intake and dis-
ease group into an exploratory linear regression model,
only dose (P < 0.001) and iron intake category
(P < 0.01) had a statistically signiﬁcant effect on change
in LIC (P = 0.15 for disease group, P = 0.61 for inter-
action term). The same was observed when evaluating
iron excretion (mg⁄kg⁄d) as the dependent variable, with
no difference between disease groups but a statistically
signiﬁcant dose effect (P < 0.001, Fig. 2). Furthermore,
iron-chelating efﬁciency is essentially the same in MDS
and other patient groups (Table 2). These results there-
fore show that in addition to dose, the degree of transfu-
sional iron intake is a key factor governing the outcome
of iron chelation therapy across different diseases.
Safety
Deferasirox treatment was associated with a deﬁned
safety proﬁle that was clinically manageable with regular
patient monitoring. Dose was temporarily interrupted in
24 (51.1%), 7 (23.3%), 10 (45.5%) and 30 (35.3%)
patients, and adjusted on at least one occasion in 28
(59.6%), 9 (30.0%), 14 (63.6%) and 38 (44.7%) patients
in the MDS, DBA, other anaemia and b-thalassaemia
groups, respectively. Dose adjustments and interruptions
were primarily due to adverse events or based on labora-
tory test results and had little impact on the overall
exposure to deferasirox, as shown by the overall relative
dose intensity (dose during study divided by initial dose)
of 0.95. The proportions of patients who permanently
discontinued treatment are shown in Table 1. Five deaths
were reported during the study (four patients with MDS
and one with DBA); three were due to a combination of
neutropenia and sepsis [two patients had neutropenia at
study entry (including the patient with DBA), and one
developed neutropenia following chemotherapy with 5-
azacytidine], one was due to pulmonary embolism and
one was due to cardio-respiratory arrest. None of the
deaths were considered by the independent Program
Safety Board to be related to administration of study
drug.
Figure 1 Separate regression lines derived from a linear model for
each disease are shown in this ﬁgure together with symbols indicat-
ing the mean changes in LIC and ferritin by disease group and dose
(as summarised in Table 2). When analysing the data across disease
groups (regression line not shown), an overall LIC change over 1 yr is
predicted as )3.36 + 0.003 times change in ferritin (Pearson’s correla-
tion coefﬁcient = 0.59). Based on this linear model, a reduction in
ferritin of 1000 lg⁄L predicts a reduction of approximately 6 mg Fe⁄g
dw in LIC.
Figure 2 Iron excretion across dose and disease groups. The average
iron excretion in mg⁄kg⁄d (±SD) is shown by disease group for doses
above 5 mg⁄kg⁄d. There is a dose effect on iron excretion
(P < 0.001), with no statistically signiﬁcant difference in disease
groups (P = 0.14). The overall average iron excretion is 0.22, 0.44 and
0.53 mg⁄kg⁄d for doses of 10, 20 and 30 mg⁄kg⁄d, respectively.
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tionship to study drug were transient gastrointestinal
events in 45.6% of patients, including abdominal pain,
nausea, vomiting, diarrhoea and constipation, as well as
skin rash in 8.7% of patients. These symptoms rarely
required prolonged dose adjustment or interruption.
Increases in serum creatinine >33% above baseline were
observed in 73 patients (39.7%), most frequently at doses
of 20 and 30 mg⁄kg⁄d. These increases were typically
seen at the start of treatment, were non-progressive and
generally remained within the normal range. No patient
had a progressive increase in serum creatinine and no
patient developed a serum creatinine level that was >2
times the ULN. Increases in serum creatinine led to dose
reductions in 32 patients (17.4%; all treated at 20 or
30 mg⁄kg⁄d), and contributed to discontinuation in four
patients (2.1%). Serum creatinine levels declined follow-
ing dose reduction in 14 patients and were non-progres-
sive in the remaining patients. Elevated alanine
aminotransferase (ALT) levels (>5 times the ULN at ‡2
consecutive postbaseline visits) were observed in 14
patients (7.6%), all but one of whom had elevated levels
at baseline. At baseline, median ALT values were 18, 23,
39 and 60 U⁄L in the four dose groups, respectively,
with the highest values observed in patients with the
highest LIC who then received the highest deferasirox
dose. At study end, the overall median changes in ALT
(61, 19, )6 and )20 U⁄L, respectively) corresponded to
the observed iron accumulation, iron balance and iron
reduction observed with deferasirox doses of 5, 10, 20
and 30 mg⁄kg⁄d, respectively. No patient underwent
dose reduction⁄interruption or discontinued because of
increases in transaminase levels.
There were no cases of arthralgia considered by the
investigators to be related to study drug. Deafness, hypo-
acusis or sudden hearing loss was reported in ﬁve
patients, two cases of which (1.1%) were considered by
the investigators to be possibly related to study drug.
Cataract formation was reported as an adverse event in
two patients (1.1%); both cases were considered by the
investigators to be unrelated to study drug.
In total, nine patients with a normal absolute neutro-
phil count (ANC) at study start developed neutropenia
(ANC < 1.50 · 10
9⁄La t‡2 consecutive postbaseline vis-
its) during the study (three with MDS, two with DBA,
three with another anaemia and one with b-thalassae-
mia). The patient with b-thalassaemia had an ANC of
approximately 1.0 · 10
9⁄L on two occasions, which nor-
malised without either dose interruption or reduction,
making a relationship to study drug extremely unlikely.
There were no cases of neutropenia, agranulocytosis or
thrombocytopenia considered by the investigators to be
related to study drug. There were no clinically signiﬁcant
changes in serum copper and zinc levels. A single episode
of QT prolongation, not assessed as drug related,
occurred in association with hypocalcaemia in a patient
with b-thalassaemia. Paediatric growth and development
proceeded normally, although the small number of pae-
diatric patients and the absence of a comparator group
do not allow deﬁnitive conclusions.
Discussion
This is the ﬁrst study to compare the response to iron
chelation therapy in MDS, DBA and other rare
anaemias with that seen in b-thalassaemia. Treatment
with deferasirox resulted in a similar pattern of dose-
dependent iron excretion in patients with MDS, rare
anaemias and b-thalassaemia (Fig. 2). This is consistent
with the similar efﬁciency of iron chelation observed
across each of these disease groups (Table 2).
The inﬂuence of transfusional iron intake on iron
balance is consistent with the differences in LIC changes
across the different disease groups. Patients with MDS,
who had the lowest mean iron intake, also showed the
largest dose-dependent reductions in LIC. Conversely,
patients with DBA, who had the highest average transfu-
sional iron intake, showed the smallest reductions in
LIC. Therefore, provided the differences in transfusional
iron loading rate are accounted for, the response to che-
lation with deferasirox is similar across the different
types of transfusion-dependent anaemia studied.
Patients with b-thalassaemia had higher LIC values at
study start compared with a recent study (9). This is
likely because b-thalassaemia patients enrolled in this
study were selected on the basis of the previous poor
chelation with DFO, whereas previously compliant b-
thalassaemia patients were included in the published
study. Nevertheless, the response to treatment with defer-
asirox is similar in both studies.
The change in serum ferritin over time correlated with
changes in LIC across all disease groups (Fig. 1). This is
in line with previous ﬁndings in patients with b-thalas-
saemia treated with DFO or deferasirox (9, 20). As LIC
has been shown to accurately predict total body iron lev-
els (16), these ﬁndings support the use of regular serum
ferritin assessments for the monitoring of deferasirox
therapy. Thus, while a single serum ferritin level has limi-
tations for the accurate prediction of total body iron
burden, the trend in ferritin levels with deferasirox treat-
ment correlates with the change in LIC values. Monthly
changes in serum ferritin showed a similar trend across
all the disease groups studied, suggesting that the chelat-
able iron pools in the liver and their relationship to
changes in serum ferritin are similar in patients with
MDS and b-thalassaemia. Thus, a downward trend in
serum ferritin levels with deferasirox therapy is likely due
to a decrease in body iron burden. However, we
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observed in this study. The high SDs associated with
mean serum ferritin change (Table 2) show that even at
a deferasirox dose of 30 mg⁄kg⁄d, some individual
patients may not experience a reduction in serum ferritin.
Despite this variability, the overall results suggest that
serum ferritin trends over time may be used to inform
decisions about dose adjustment in MDS as well as b-
thalassaemia and rare transfusion-dependent anaemias.
Deferasirox had a deﬁned, clinically manageable safety
proﬁle across all disease groups and age ranges studied.
As some patients with LIC assessed by SQUID may
have been assigned to a lower deferasirox dose than if
they had been assessed by biopsy, they may therefore
have been at a lower risk of treatment-related adverse
events. The most common adverse events considered to
be treatment related were gastrointestinal symptoms,
which were mild to moderate in severity and generally
resolved spontaneously without the need for discontinu-
ing treatment. In line with the ﬁndings from a previous
study (9), the observed elevations in serum creatinine
levels were dose-related, non-progressive and most
responded to dose reduction or interruption. These
ﬁndings provide no evidence for an increased risk of pro-
gressive renal dysfunction with deferasirox therapy in
patients with MDS. Increases in serum creatinine level
may reﬂect a haemodynamic effect on the kidney
induced by the chelating activity of deferasirox; investi-
gations are ongoing to explore the effects of deferasirox
on the kidney. Meanwhile, deferasirox should be used
with caution in patients with renal impairment and
serum creatinine should be monitored monthly in all
patients. The nine cases of neutropenia observed in this
study were considered by the investigators to be related
to the underlying disease. The observation that there
were no drug-induced cases of neutropenia, agranulocy-
tosis or thrombocytopenia is of particular importance in
patients with rare anaemia who may have multiple and
often progressive bone marrow defects in addition to
ineffective erythropoiesis. Thus, there is no evidence in
this study of disease-speciﬁc toxicity or tolerability issues
with deferasirox and, in particular, no evidence of a tox-
icity proﬁle that is unusual to patients with MDS.
As there are currently no published reports on intra-
and inter-centre variability of SQUID, nor any published
multicentre validation studies, in order to evaluate any
potential bias in the results, we performed additional
analyses evaluating the impact of the SQUID data on
the overall ﬁndings of the study. Both this study and a
previous cross-validation substudy (19) have observed
that LIC values obtained using SQUID are approxi-
mately half those obtained by biopsy. As such, in this
analysis LIC data from SQUID were multiplied by a fac-
tor of two, which was considered appropriate to correct
for the discrepancy. Therefore, combined with the wet-
to-dry weight conversion factor of 3.33 (21), the overall
conversion factor was 6.66. A subsequent sensitivity anal-
ysis has demonstrated that the use of slightly different
conversion factors [e.g. 2.17 (1⁄0.46) based on the previ-
ous study (19), or 2.3 based on the two average baseline
LICs reported in this study] does not affect the signiﬁ-
cance of the results or, therefore, the overall conclusions
that have been drawn. Importantly, the signiﬁcance also
remains unaffected if SQUID data are excluded from the
analyses altogether and only LIC data derived from
biopsy are included. Further, if changes in LIC over 1 yr
are categorised as increase vs. no increase, which is inde-
pendent of the absolute magnitude of change, all patients
with MDS and 55% of DBA patients who received 20 or
30 mg⁄kg⁄d had a reduction, while 44% of MDS
patients and 25% of DBA patients who were treated with
5o r1 0m g ⁄kg⁄d also had a reduction. It can therefore
be concluded that despite the known limitations of the
SQUID technique and the lack of published validation
studies, inclusion of these data does not introduce undue
bias into the overall ﬁndings of this study.
In conclusion, this 1-yr prospective trial shows that
iron-overloaded patients with MDS, DBA and other rare
anaemias respond to deferasirox in a similar dose-depen-
dent manner as patients with b-thalassaemia, both with
respect to efﬁcacy and safety parameters. Changes in
serum ferritin and LIC correlated, supporting the use of
regular serum ferritin assessments to monitor deferasirox
therapy. Deferasirox dosing should be guided by the thera-
peutic goal, accounting for both the existing iron burden
and ongoing transfusional iron loading. The availability of
a convenient, once-daily, oral iron chelator that has pre-
dictable, dose-dependent effects on iron balance and a
deﬁned, clinically manageable safety proﬁle across a range
of transfusion-dependent anaemias, including MDS,
should allow a greater number of regularly transfused
patients to gain beneﬁt from iron chelation therapy.
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